Regeneron Pharmaceuticals Non-GAAP EPS of $20.07 beats by $3.82, revenue of $5.1B beats by $540M (NASDAQ:REGN)

Regeneron Pharmaceuticals reported Q3 Non-GAAP EPS of $20.07, exceeding estimates by $3.82, and revenue of $5.1B, up 36% Y/Y and $540M above expectations. The company also provided full-year 2026 financial guidance. According to the company, the results indicate strong performance and growth.

Original reporting
Published Oct 30, 2026, 10:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 10:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Regeneron Pharmaceuticals Non-GAAP EPS of $20.07 beats by $3.82, revenue of $5.1B beats by $540M (NASDAQ:REGN) — source image
Decision brief

The 30-second read

$REGNBullishHigh
01

Why it matters

The surprise earnings could trigger a short‑term rally in REGN and lift sentiment in the biotech space.

02

Market read

First‑report earnings beat for a major biotech; high trading relevance.

03

What to watch

Potential headwinds from upcoming regulatory reviews or pipeline setbacks.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Regeneron posted Q3 results ahead of schedule, beating both EPS and revenue expectations.

Company-level read

Ticker impact

$REGNBullishHigh confidence
Context

Q3 non‑GAAP EPS of $20.07 beat expectations by $3.82 and revenue of $5.1B beat by $540M.

Expected impact

upward pressure as the market prices in the earnings beat

Evidence & confidence

Both EPS and revenue exceeded consensus, a material surprise for a large‑cap biotech.

Market effects

Biotech and pharma sector may see broader rally on strong earnings.

U.S. markets likely to open higher on the news.

Limited to investors tracking U.S. biotech earnings.

Counterpoint

Some analysts may view the beat as already priced in, limiting upside.

Key entities

  • Regeneron Pharmaceuticals, Inc.

    Large‑cap biotech company reporting Q3 earnings.

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.

$REGNMed

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis

Regeneron Pharmaceuticals received FDA approval for Livsayis, a siRNA therapy for generalized myasthenia gravis (gMG). It is the first of its kind and is administered subcutaneously four times a year. The approval was based on positive phase III NIMBLE study results, showing significant symptom improvement. Livsayis carries a Boxed Warning for serious infections. Regeneron's stock has risen 22.9% year-to-date. The therapy is under review in the EU and planned for other regions.